Amantadine and the End-Stage Dementia of Alzheimerʼs Type
- 1 May 1989
- journal article
- research article
- Published by Southern Medical Association in Southern Medical Journal
- Vol. 82 (5) , 550-554
- https://doi.org/10.1097/00007611-198905000-00004
Abstract
Significant improvement of mental status was noted with amantadine therapy in three patients in whom autopsy subsequently showed Alzhiemer''s disease. Two patients showed a dramatic improvement during the treatment. Their mute, immobile states were reversed and they were able to speak a few coherent words. Their mental status deteriorated when the drug was withdrawn. Transient clinical improvement was noted when amantadine was reinstituted. In all patients EEG showed typical repetitive periodic sharp waves (PSW) similar to those seen in Creutzfeldt-Jacob diseases. Alterations of PSW accompanied the initial clinical improvement. We speculate the amantadine acts as a central stimulant by enhancing the release of central endogenous dopamine and possibly other neurotransmitters.This publication has 6 references indexed in Scilit:
- Fluctuations in plasma dopamine level impair memory in Parkinson's diseaseNeurology, 1987
- β Amyloid Gene Duplication in Alzheimer's Disease and Karyotypically Normal Down SyndromeScience, 1987
- Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer TypeNew England Journal of Medicine, 1986
- The Effect of Amantadine on Arousal and EEG Patterns in Creutzfeldt-Jakob DiseaseArchives of Neurology, 1983
- Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementiaNeurology, 1982
- Antiviral Activity of 1-Adamantanamine (Amantadine)Science, 1964